US Stock MarketDetailed Quotes

ALDX Aldeyra Therapeutics

Watchlist
  • 5.150
  • +0.250+5.10%
Trading Dec 16 13:18 ET
306.67MMarket Cap-6.87P/E (TTM)

Aldeyra Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Total revenue
0
0
0
0
0
0
0
0
0
0
Operating revenue
--0
--0
--0
--0
--0
--0
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
68.97%16.14M
74.11%18.01M
-44.10%9.39M
-31.73%42.79M
-55.48%6.1M
-35.40%9.55M
-41.62%10.34M
1.94%16.8M
11.49%62.68M
-11.08%13.7M
Selling and administrative expenses
42.78%3.7M
-10.11%3.04M
-42.34%3.21M
-13.26%13.34M
-62.00%1.8M
-20.22%2.59M
7.49%3.38M
31.02%5.57M
36.26%15.37M
84.77%4.74M
-General and administrative expense
42.78%3.7M
-10.11%3.04M
-42.34%3.21M
-13.26%13.34M
-62.00%1.8M
-20.22%2.59M
7.49%3.38M
31.02%5.57M
36.26%15.37M
84.77%4.74M
Research and development costs
78.71%12.44M
114.99%14.97M
-44.97%6.18M
-37.73%29.46M
-52.04%4.3M
-39.67%6.96M
-52.21%6.96M
-8.16%11.24M
5.27%47.31M
-30.21%8.96M
Operating profit
-68.97%-16.14M
-74.11%-18.01M
44.10%-9.39M
31.73%-42.79M
55.48%-6.1M
35.40%-9.55M
41.62%-10.34M
-1.94%-16.8M
-11.49%-62.68M
11.08%-13.7M
Net non-operating interest income expense
-24.86%1.02M
-14.42%1.16M
10.45%1.31M
701.34%5.25M
69.24%1.34M
489.43%1.36M
2,153.50%1.36M
489.91%1.19M
142.10%655.35K
326.84%794.63K
Non-operating interest income
-20.94%1.5M
-13.01%1.64M
7.83%1.81M
211.69%7.32M
48.08%1.86M
193.45%1.9M
446.72%1.88M
1,556.00%1.68M
1,167.49%2.35M
1,904.52%1.26M
Non-operating interest expense
-11.04%479.25K
-9.40%477.6K
1.47%498.53K
22.27%2.07M
11.60%514.26K
29.22%538.74K
28.45%527.14K
21.02%491.29K
-2.76%1.69M
11.60%460.82K
Other net income (expense)
Income before tax
-84.60%-15.11M
-87.47%-16.85M
48.24%-8.08M
39.47%-37.54M
63.16%-4.75M
43.75%-8.19M
49.46%-8.99M
6.98%-15.62M
-7.35%-62.02M
18.11%-12.9M
Income tax
Net income
-84.60%-15.11M
-87.47%-16.85M
48.24%-8.08M
39.47%-37.54M
63.16%-4.75M
43.75%-8.19M
49.46%-8.99M
6.98%-15.62M
-7.35%-62.02M
18.11%-12.9M
Net income continuous Operations
-84.60%-15.11M
-87.47%-16.85M
48.24%-8.08M
39.47%-37.54M
63.16%-4.75M
43.75%-8.19M
49.46%-8.99M
6.98%-15.62M
-7.35%-62.02M
18.11%-12.9M
Minority interest income
Net income attributable to the parent company
-84.60%-15.11M
-87.47%-16.85M
48.24%-8.08M
39.47%-37.54M
63.16%-4.75M
43.75%-8.19M
49.46%-8.99M
6.98%-15.62M
-7.35%-62.02M
18.11%-12.9M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-84.60%-15.11M
-87.47%-16.85M
48.24%-8.08M
39.47%-37.54M
63.16%-4.75M
43.75%-8.19M
49.46%-8.99M
6.98%-15.62M
-7.35%-62.02M
18.11%-12.9M
Basic earnings per share
-78.57%-0.25
-86.67%-0.28
48.15%-0.14
39.62%-0.64
63.64%-0.08
44.00%-0.14
50.00%-0.15
6.90%-0.27
0.93%-1.06
18.52%-0.22
Diluted earnings per share
-78.57%-0.25
-86.67%-0.28
48.15%-0.14
39.62%-0.64
63.64%-0.08
44.00%-0.14
50.00%-0.15
6.90%-0.27
0.93%-1.06
18.52%-0.22
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Total revenue 0000000000
Operating revenue --0--0--0--0--0--0--0--0--0--0
Cost of revenue
Gross profit
Operating expense 68.97%16.14M74.11%18.01M-44.10%9.39M-31.73%42.79M-55.48%6.1M-35.40%9.55M-41.62%10.34M1.94%16.8M11.49%62.68M-11.08%13.7M
Selling and administrative expenses 42.78%3.7M-10.11%3.04M-42.34%3.21M-13.26%13.34M-62.00%1.8M-20.22%2.59M7.49%3.38M31.02%5.57M36.26%15.37M84.77%4.74M
-General and administrative expense 42.78%3.7M-10.11%3.04M-42.34%3.21M-13.26%13.34M-62.00%1.8M-20.22%2.59M7.49%3.38M31.02%5.57M36.26%15.37M84.77%4.74M
Research and development costs 78.71%12.44M114.99%14.97M-44.97%6.18M-37.73%29.46M-52.04%4.3M-39.67%6.96M-52.21%6.96M-8.16%11.24M5.27%47.31M-30.21%8.96M
Operating profit -68.97%-16.14M-74.11%-18.01M44.10%-9.39M31.73%-42.79M55.48%-6.1M35.40%-9.55M41.62%-10.34M-1.94%-16.8M-11.49%-62.68M11.08%-13.7M
Net non-operating interest income expense -24.86%1.02M-14.42%1.16M10.45%1.31M701.34%5.25M69.24%1.34M489.43%1.36M2,153.50%1.36M489.91%1.19M142.10%655.35K326.84%794.63K
Non-operating interest income -20.94%1.5M-13.01%1.64M7.83%1.81M211.69%7.32M48.08%1.86M193.45%1.9M446.72%1.88M1,556.00%1.68M1,167.49%2.35M1,904.52%1.26M
Non-operating interest expense -11.04%479.25K-9.40%477.6K1.47%498.53K22.27%2.07M11.60%514.26K29.22%538.74K28.45%527.14K21.02%491.29K-2.76%1.69M11.60%460.82K
Other net income (expense)
Income before tax -84.60%-15.11M-87.47%-16.85M48.24%-8.08M39.47%-37.54M63.16%-4.75M43.75%-8.19M49.46%-8.99M6.98%-15.62M-7.35%-62.02M18.11%-12.9M
Income tax
Net income -84.60%-15.11M-87.47%-16.85M48.24%-8.08M39.47%-37.54M63.16%-4.75M43.75%-8.19M49.46%-8.99M6.98%-15.62M-7.35%-62.02M18.11%-12.9M
Net income continuous Operations -84.60%-15.11M-87.47%-16.85M48.24%-8.08M39.47%-37.54M63.16%-4.75M43.75%-8.19M49.46%-8.99M6.98%-15.62M-7.35%-62.02M18.11%-12.9M
Minority interest income
Net income attributable to the parent company -84.60%-15.11M-87.47%-16.85M48.24%-8.08M39.47%-37.54M63.16%-4.75M43.75%-8.19M49.46%-8.99M6.98%-15.62M-7.35%-62.02M18.11%-12.9M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -84.60%-15.11M-87.47%-16.85M48.24%-8.08M39.47%-37.54M63.16%-4.75M43.75%-8.19M49.46%-8.99M6.98%-15.62M-7.35%-62.02M18.11%-12.9M
Basic earnings per share -78.57%-0.25-86.67%-0.2848.15%-0.1439.62%-0.6463.64%-0.0844.00%-0.1450.00%-0.156.90%-0.270.93%-1.0618.52%-0.22
Diluted earnings per share -78.57%-0.25-86.67%-0.2848.15%-0.1439.62%-0.6463.64%-0.0844.00%-0.1450.00%-0.156.90%-0.270.93%-1.0618.52%-0.22
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------Unqualified Opinion--------Unqualified Opinion--
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Symbol Mini Chart % Chg
MARA Holdings
MARA
+11.17%
MicroStrategy
MSTR
+6.61%
Tesla
TSLA
+4.80%
Alphabet-A
GOOGL
+4.67%
Alphabet-C
GOOG
+4.67%

Unlock the Full List